In healthy-donor human neutrophils, 10 μM 6-gingerol reduced NET release elicited by RNP immune complexes or APS IgG over 3 hours, as assessed by NET-associated MPO activity and microscopy. A separate 3-hour viability control showed no significant reduction with 1 mM 6-gingerol; this finding has a short-term assay scope. [1]
Inhibition of cAMP-specific PDE activity in neutrophil lysate
Biochemical assay · Lysates from primary human neutrophils [1]
At 10 μM, 6-gingerol reduced cAMP-specific PDE activity relative to the untreated lysate reaction. Rolipram was a comparator; this assay does not establish PDE4 selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM 6-gingerol; comparator rolipram 0.1 μM
- Exposure duration
- 1 hour reaction at 37°C
- Method
- 6-Gingerol or rolipram added to the reaction containing human neutrophil lysate supernatant; cAMP-specific PDE activity measured with a Bridge-It cAMP-PDE assay kit.
- Reported limits
- Treatment solvent and exact PDE isoform composition not reported in the relevant assay methods; no purified PDE4 selectivity or IC50 experiment.
Methods and source locations
Compound reported in the paper: 6-Gingerol; Compound label in the paper: 6-Gingerol
Evidence applies to 6-gingerol as reported in the paper; no validation of the stereochemical purity or performance of a current Adooq lot.
Figure 3A; Methods: Measurement of PDE activity
cAMP-specific PDE activity relative to mean control: Bridge-It cAMP-PDE fluorescence assay; activity normalized to mean control values. Figure 3 caption reports mean and SEM, n = 3–4 independent experiments across panels. — Results: 6-Gingerol inhibits cAMP-specific PDE activity; Figure 3A and caption; Methods: Measurement of PDE activity
Suppression of autoantibody-associated NET release
Cell-based study · Primary human neutrophils from healthy volunteers stimulated separately with RNP immune complexes or APS IgG [1]
6-Gingerol reduced stimulated NET-associated MPO activity. Neutrophil-elastase/DNA microscopy supported reduced extracellular NET structures. A separate short-term viability control showed no significant change with 1 mM 6-gingerol.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM 6-gingerol; RNP immune complexes or APS IgG at 10 μg/mL
- Exposure duration
- 3 hours
- Method
- Primary human neutrophils from healthy volunteers exposed to the indicated sterile autoimmune stimulus with or without 6-gingerol; NET-associated MPO activity and immunofluorescence assessed.
- Co-treatment
- RNP immune complexes or APS IgG are activating stimuli, tested separately.
- Reported limits
- The 6-gingerol treatment solvent, catalog number and enantiomeric composition are not specified in the relevant methods. The separate viability control used 1 mM for 3 hours.
Methods and source locations
Compound reported in the paper: 6-Gingerol; Compound label in the paper: 6-Gingerol
Evidence applies to 6-gingerol as reported in the paper; no validation of the stereochemical purity or performance of a current Adooq lot.
Figure 1E–G; Supplemental Figure 1C; Methods: Human neutrophil purification and NETosis assays; Immunofluorescence microscopy
NET-associated myeloperoxidase after RNP immune-complex or APS-IgG stimulation: Enzymatic activity of nuclease-liberated NET-associated MPO; unstimulated and stimulus-only controls. Figure 1E–F: mean and SEM, n = 3 independent experiments; Dunnett-corrected one-way ANOVA. No exact effect size inferred from bars. — Figure 1E–F and caption; Results: Gingerols inhibit NETosis elicited by lupus and APS autoantibodies; Methods: Human neutrophil purification and NETosis assays
Extracellular NET structures: Immunofluorescence microscopy; vehicle comparator; Hoechst-stained DNA and extracellular neutrophil elastase. Representative images do not provide an independent quantitative effect estimate. — Figure 1G and caption; Methods: Immunofluorescence microscopy
Short-term neutrophil viability in a separate control: Trypan-blue exclusion/counting; untreated control and staurosporine positive control. Mean and SEM, n = 3 independent experiments; NS as labeled. This does not establish longer-term or clinical safety. — Supplemental Figure 1C and caption (SI PDF page 2)